{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling in tumor tissue",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "While the interferon response was robustly induced, the study noted that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "Interferon-associated antigen processing and presentation pathways increase following intratumoral mRNA vaccination",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        }
      ],
      "caveat": "The expansion of the antigen presentation landscape was demonstrated in preclinical models, but translation to human tumors requires further validation."
    },
    {
      "claim_id": "C03",
      "claim": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells following vaccination",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        },
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        }
      ],
      "caveat": "Increased CD8+ T-cell infiltration was observed with combination therapy, but the direct causal link between expanded MHC-I peptidome and T-cell response requires additional mechanistic studies."
    },
    {
      "claim_id": "C04",
      "claim": "PD-L1 pathway activity increases after mRNA vaccination, creating rationale for combining with checkpoint blockade",
      "strength": "strong",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable",
          "line_ref": "L32"
        }
      ],
      "caveat": "The upregulation of PD-L1 provides mechanistic justification for the combination approach, though optimal timing of vaccination relative to ICI initiation requires clarification."
    },
    {
      "claim_id": "C05",
      "claim": "Combined intratumoral mRNA vaccination and anti-PD-L1 therapy improves tumor control in preclinical models",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Vehicle-only treatment did not produce durable tumor control in non-immunogenic models. ICI-only treatment had limited activity in low-immunogenic baseline settings.",
          "line_ref": "L36"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "While combination therapy showed efficacy in mouse models, mouse model effects may not map one-to-one to all human tumors, limiting direct translational interpretation."
    },
    {
      "claim_id": "C06",
      "claim": "Patients with prior SARS-CoV-2 mRNA vaccination showed improved survival outcomes under ICI treatment in retrospective analysis",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing relative to ICI initiation varied across patients."
    }
  ]
}